Target intelligence / Profile preview

HECT and RLD domain containing E3 ubiquitin protein ligase 2 (HERC2)

Target
HERC2
Molecular classification
Enzyme, E3 ubiquitin ligase (HECT-type), Large HERC family, Protein with RCC1-like domain (RLD)
01

Overview

HECT and RLD domain containing E3 ubiquitin protein ligase 2 (HERC2) is a giant, multifunctional E3 ubiquitin ligase of the large HERC family, characterized by the presence of a C-terminal "homologous to E6AP carboxyl terminus" (HECT) domain and multiple RCC1-like (RLD) domains[1][5][7]. HERC2 plays a major role in ubiquitination, marking specific proteins for proteasomal degradation. Key substrates and pathways regulated by HERC2 include DNA repair proteins (e.g., BRCA1, XPA), cell cycle proteins, and the iron homeostasis regulator FBXL5[1][2][5][6][7].\nHERC2 functions in pivotal cellular and physiological processes such as DNA damage response—facilitating protein recruitment to damaged chromatin, controlling the activity of p53 by promoting its oligomerization and transcriptional activation, and modulating circadian oscillation of nucleotide excision repair[1][3][6][7]. It also regulates iron metabolism, centrosome stability, intracellular trafficking, and pigmentation through OCA2 gene regulation[2][5][7].\nGenetic variants in HERC2 are linked to human eye and skin color variation as well as increased skin cancer risk; disruptions or mutations in HERC2 are implicated in cancer, neurodevelopmental/neurodegenerative diseases, and other complex disorders, reflecting its broad physiological roles and importance in maintaining cellular homeostasis[1][2][5][6][7]. No currently approved drugs specifically and selectively target HERC2, but it could be considered a potential future therapeutic target due to its regulatory functions within important signaling and homeostatic pathways.

Other names
E3 ubiquitin-protein ligase HERC2jdf2p528D15F37S1HECT domain and RCC1-like domain-containing protein 2HECT-type E3 ubiquitin transferase HERC2MRT38SHEP1probable E3 ubiquitin-protein ligase HERC2
02

Mechanism of action

Drugs affecting HERC2 function would potentially alter protein ubiquitination, DNA repair fidelity, p53-mediated transcription, cell cycle progression, and iron metabolism[1][3][7].

03

Biological functions

Protein ubiquitylation (targeting proteins for proteasomal degradation)DNA damage response and repairRegulation of p53 signaling (oligomerization and transcriptional activity)Cell cycle controlCentrosome assembly and stabilityRegulation of iron homeostasisRegulation of pigmentationRegulation of endosomal trafficking
04

Disease associations

Cancer (tumorigenesis, tumor suppression, breast cancer)Neurodegenerative diseaseSkin pigmentation disorders (including risk for skin cancer)DNA repair disorders (e.g., through modulation of nucleotide excision repair)Other: Disorders involving iron metabolism, sterility in model organisms
05

Safety considerations

Potential for broad disruptions in protein homeostasis, cell cycle, DNA repair, and apoptosis if HERC2 function is modulated across multiple tissues[1][5][7]Risk of off-target effects given pleiotropic roles (including neurological, hematological, and skin effects)Impact on iron metabolism, posing risk of anemia or iron overloadInteractions with p53, raising the possibility of tumorigenic effects if function is lost or hyperactivated
06

Interacting drugs

No specific drugs directly targeting HERC2 are described in currently available scientific literature[1][3][5][7]. HERC2 influences sensitivity to DNA damaging agents like cisplatin[1], but is not currently the established direct pharmacological target of any approved drug.
07

Biomarkers

Intronic variants/SNPs in HERC2 (notably affecting pigmentation and skin cancer risk)[2][5]HERC2 expression levels in cancer prognosis[4]

Beyond the preview

Go deeper on HECT and RLD domain containing E3 ubiquitin protein ligase 2 (HERC2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HECT and RLD domain containing E3 ubiquitin protein ligase 2 (HERC2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call